APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tenofovir Disoproxil Fumarate Tablets

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Tenofovir Disoproxil Fumarate Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025196 pages

Choose your research edition.

Industry ResearchTenofovir Disoproxil Fumarate Tablets Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Tenofovir Disoproxil Fumarate Tablets Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Tenofovir Disoproxil Fumarate Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tenofovir Disoproxil Fumarate Tablets Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Tenofovir Disoproxil Fumarate Tablets Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Tenofovir Disoproxil Fumarate Tablets market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Tenofovir Disoproxil Fumarate Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tenofovir Disoproxil Fumarate Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tenofovir Disoproxil Fumarate Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Tenofovir Disoproxil Fumarate Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Tenofovir Disoproxil Fumarate Tablets include Aurobindo Pharma, Gilead Sciences, GSK, Hetero Drugs, Strides Pharma, Teva Pharmaceuticals, Chengdu Beite Pharmaceutical, Haisco Pharmaceutical and Shijiazhuang Lonzeal Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tenofovir Disoproxil Fumarate Tablets market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tenofovir Disoproxil Fumarate Tablets and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tenofovir Disoproxil Fumarate Tablets sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tenofovir Disoproxil Fumarate Tablets market size, projected growth trends, production technologies, key applications, and end-use industries.

Tenofovir Disoproxil Fumarate Tablets Segment by Company

Aurobindo Pharma

Gilead Sciences

GSK

Hetero Drugs

Strides Pharma

Teva Pharmaceuticals

Chengdu Beite Pharmaceutical

Haisco Pharmaceutical

Shijiazhuang Lonzeal Pharmaceuticals

Luoxin Pharmaceuticals

Qilu Pharmaceutical

Shanghai Haini Pharmaceutical

Beijing SL Pharmaceutical

Sichuan Kelun Pharmaceutical

Chongqing Yaoyou Pharmaceutical

Zhejiang Sukean Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Tenofovir Disoproxil Fumarate Tablets Segment by Type

Original Drug

Generic Drug

Tenofovir Disoproxil Fumarate Tablets Segment by Application

HIV-1 Infection

Chronic Hepatitis B

Tenofovir Disoproxil Fumarate Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tenofovir Disoproxil Fumarate Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tenofovir Disoproxil Fumarate Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tenofovir Disoproxil Fumarate Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tenofovir Disoproxil Fumarate Tablets market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Tenofovir Disoproxil Fumarate Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Tenofovir Disoproxil Fumarate Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Tenofovir Disoproxil Fumarate Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Tenofovir Disoproxil Fumarate Tablets Industry Trends Table 2. Tenofovir Disoproxil Fumarate Tablets Industry Drivers Table 3. Tenofovir Disoproxil Fumarate Tablets Industry Opportunities and Challenges Table 4. Tenofovir Disoproxil Fumarate Tablets Industry Restraints Table 5. Global Tenofovir Disoproxil Fumarate Tablets Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Tenofovir Disoproxil Fumarate Tablets Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Tenofovir Disoproxil Fumarate Tablets Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Manufacturers Table 9. Global Tenofovir Disoproxil Fumarate Tablets Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Tenofovir Disoproxil Fumarate Tablets Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Tenofovir Disoproxil Fumarate Tablets Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Tenofovir Disoproxil Fumarate Tablets Manufacturers, Product Type & Application Table 13. Global Tenofovir Disoproxil Fumarate Tablets Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Tenofovir Disoproxil Fumarate Tablets by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Original Drug Table 17. Major Manufacturers of Generic Drug Table 18. Global Tenofovir Disoproxil Fumarate Tablets Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Tenofovir Disoproxil Fumarate Tablets Sales by Type (2021-2026) & (K Units) Table 20. Global Tenofovir Disoproxil Fumarate Tablets Sales by Type (2027-2032) & (K Units) Table 21. Global Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Type (2021-2026) Table 22. Global Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Type (2027-2032) Table 23. Global Tenofovir Disoproxil Fumarate Tablets Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Tenofovir Disoproxil Fumarate Tablets Revenue by Type (2021-2026) & (K Units) Table 25. Global Tenofovir Disoproxil Fumarate Tablets Revenue by Type (2027-2032) & (K Units) Table 26. Global Tenofovir Disoproxil Fumarate Tablets Revenue Market Share by Type (2021-2026) Table 27. Global Tenofovir Disoproxil Fumarate Tablets Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of HIV-1 Infection Table 29. Major Manufacturers of Chronic Hepatitis B Table 30. Global Tenofovir Disoproxil Fumarate Tablets Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 31. Global Tenofovir Disoproxil Fumarate Tablets Sales by Application (2021-2026) & (K Units) Table 32. Global Tenofovir Disoproxil Fumarate Tablets Sales by Application (2027-2032) & (K Units) Table 33. Global Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Application (2021-2026) Table 34. Global Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Application (2027-2032) Table 35. Global Tenofovir Disoproxil Fumarate Tablets Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Tenofovir Disoproxil Fumarate Tablets Revenue by Application (2021-2026) & (K Units) Table 37. Global Tenofovir Disoproxil Fumarate Tablets Revenue by Application (2027-2032) & (K Units) Table 38. Global Tenofovir Disoproxil Fumarate Tablets Revenue Market Share by Application (2021-2026) Table 39. Global Tenofovir Disoproxil Fumarate Tablets Revenue Market Share by Application (2027-2032) Table 40. Global Tenofovir Disoproxil Fumarate Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 41. Global Tenofovir Disoproxil Fumarate Tablets Sales by Region (2021-2026) & (K Units) Table 42. Global Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Region (2021-2026) Table 43. Global Tenofovir Disoproxil Fumarate Tablets Sales Forecasted by Region (2027-2032) & (K Units) Table 44. Global Tenofovir Disoproxil Fumarate Tablets Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Tenofovir Disoproxil Fumarate Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 46. North America Tenofovir Disoproxil Fumarate Tablets Sales by Country (2021-2026) & (K Units) Table 47. North America Tenofovir Disoproxil Fumarate Tablets Sales by Country (2027-2032) & (K Units) Table 48. Europe Tenofovir Disoproxil Fumarate Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. Europe Tenofovir Disoproxil Fumarate Tablets Sales by Country (2021-2026) & (K Units) Table 50. Europe Tenofovir Disoproxil Fumarate Tablets Sales by Country (2027-2032) & (K Units) Table 51. Asia Pacific Tenofovir Disoproxil Fumarate Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Asia Pacific Tenofovir Disoproxil Fumarate Tablets Sales by Country (2021-2026) & (K Units) Table 53. Asia Pacific Tenofovir Disoproxil Fumarate Tablets Sales by Country (2027-2032) & (K Units) Table 54. South America, Middle East and Africa Tenofovir Disoproxil Fumarate Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. South America, Middle East and Africa Tenofovir Disoproxil Fumarate Tablets Sales by Country (2021-2026) & (K Units) Table 56. South America, Middle East and Africa Tenofovir Disoproxil Fumarate Tablets Sales by Country (2027-2032) & (K Units) Table 57. Global Tenofovir Disoproxil Fumarate Tablets Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Tenofovir Disoproxil Fumarate Tablets Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Tenofovir Disoproxil Fumarate Tablets Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Tenofovir Disoproxil Fumarate Tablets Revenue Market Share by Region (2021-2026) Table 61. Global Tenofovir Disoproxil Fumarate Tablets Revenue Market Share by Region (2027-2032) Table 62. Aurobindo Pharma Company Information Table 63. Aurobindo Pharma Business Overview Table 64. Aurobindo Pharma Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Aurobindo Pharma Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 66. Aurobindo Pharma Recent Development Table 67. Gilead Sciences Company Information Table 68. Gilead Sciences Business Overview Table 69. Gilead Sciences Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Gilead Sciences Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 71. Gilead Sciences Recent Development Table 72. GSK Company Information Table 73. GSK Business Overview Table 74. GSK Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. GSK Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 76. GSK Recent Development Table 77. Hetero Drugs Company Information Table 78. Hetero Drugs Business Overview Table 79. Hetero Drugs Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Hetero Drugs Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 81. Hetero Drugs Recent Development Table 82. Strides Pharma Company Information Table 83. Strides Pharma Business Overview Table 84. Strides Pharma Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Strides Pharma Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 86. Strides Pharma Recent Development Table 87. Teva Pharmaceuticals Company Information Table 88. Teva Pharmaceuticals Business Overview Table 89. Teva Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Teva Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 91. Teva Pharmaceuticals Recent Development Table 92. Chengdu Beite Pharmaceutical Company Information Table 93. Chengdu Beite Pharmaceutical Business Overview Table 94. Chengdu Beite Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Chengdu Beite Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 96. Chengdu Beite Pharmaceutical Recent Development Table 97. Haisco Pharmaceutical Company Information Table 98. Haisco Pharmaceutical Business Overview Table 99. Haisco Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Haisco Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 101. Haisco Pharmaceutical Recent Development Table 102. Shijiazhuang Lonzeal Pharmaceuticals Company Information Table 103. Shijiazhuang Lonzeal Pharmaceuticals Business Overview Table 104. Shijiazhuang Lonzeal Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Shijiazhuang Lonzeal Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 106. Shijiazhuang Lonzeal Pharmaceuticals Recent Development Table 107. Luoxin Pharmaceuticals Company Information Table 108. Luoxin Pharmaceuticals Business Overview Table 109. Luoxin Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Luoxin Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 111. Luoxin Pharmaceuticals Recent Development Table 112. Qilu Pharmaceutical Company Information Table 113. Qilu Pharmaceutical Business Overview Table 114. Qilu Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Qilu Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 116. Qilu Pharmaceutical Recent Development Table 117. Shanghai Haini Pharmaceutical Company Information Table 118. Shanghai Haini Pharmaceutical Business Overview Table 119. Shanghai Haini Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Shanghai Haini Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 121. Shanghai Haini Pharmaceutical Recent Development Table 122. Beijing SL Pharmaceutical Company Information Table 123. Beijing SL Pharmaceutical Business Overview Table 124. Beijing SL Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Beijing SL Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 126. Beijing SL Pharmaceutical Recent Development Table 127. Sichuan Kelun Pharmaceutical Company Information Table 128. Sichuan Kelun Pharmaceutical Business Overview Table 129. Sichuan Kelun Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Sichuan Kelun Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 131. Sichuan Kelun Pharmaceutical Recent Development Table 132. Chongqing Yaoyou Pharmaceutical Company Information Table 133. Chongqing Yaoyou Pharmaceutical Business Overview Table 134. Chongqing Yaoyou Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Chongqing Yaoyou Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 136. Chongqing Yaoyou Pharmaceutical Recent Development Table 137. Zhejiang Sukean Pharmaceutical Company Information Table 138. Zhejiang Sukean Pharmaceutical Business Overview Table 139. Zhejiang Sukean Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Zhejiang Sukean Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 141. Zhejiang Sukean Pharmaceutical Recent Development Table 142. Chia Tai Tianqing Pharmaceutical Company Information Table 143. Chia Tai Tianqing Pharmaceutical Business Overview Table 144. Chia Tai Tianqing Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. Chia Tai Tianqing Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 146. Chia Tai Tianqing Pharmaceutical Recent Development Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Tenofovir Disoproxil Fumarate Tablets Distributors List Table 150. Tenofovir Disoproxil Fumarate Tablets Customers List Table 151. Research Programs/Design for This Report Table 152. Authors List of This Report Table 153. Secondary Sources Table 154. Primary Sources List of Figures Figure 1. Tenofovir Disoproxil Fumarate Tablets Product Image Figure 2. Global Tenofovir Disoproxil Fumarate Tablets Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tenofovir Disoproxil Fumarate Tablets Market Size (2021-2032) & (US$ Million) Figure 4. Global Tenofovir Disoproxil Fumarate Tablets Sales (2021-2032) & (K Units) Figure 5. Global Tenofovir Disoproxil Fumarate Tablets Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Tenofovir Disoproxil Fumarate Tablets Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Original Drug Image Figure 9. Generic Drug Image Figure 10. Global Tenofovir Disoproxil Fumarate Tablets Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Tenofovir Disoproxil Fumarate Tablets Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Type (2021-2032) Figure 13. Global Tenofovir Disoproxil Fumarate Tablets Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Tenofovir Disoproxil Fumarate Tablets Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Tenofovir Disoproxil Fumarate Tablets Revenue Market Share by Type (2021-2032) Figure 16. HIV-1 Infection Image Figure 17. Chronic Hepatitis B Image Figure 18. Global Tenofovir Disoproxil Fumarate Tablets Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Tenofovir Disoproxil Fumarate Tablets Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Application (2021-2032) Figure 21. Global Tenofovir Disoproxil Fumarate Tablets Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Tenofovir Disoproxil Fumarate Tablets Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Tenofovir Disoproxil Fumarate Tablets Revenue Market Share by Application (2021-2032) Figure 24. North America Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 25. North America Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Country (2021-2032) Figure 26. U.S. Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 27. Canada Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Mexico Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Europe Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Country (2021-2032) Figure 31. Germany Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 32. France Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 33. U.K. Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Italy Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Netherlands Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Asia Pacific Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Country (2021-2032) Figure 38. China Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Japan Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 40. South Korea Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Southeast Asia Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 42. India Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Australia Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South America, Middle East and Africa Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Country (2021-2032) Figure 46. Brazil Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Africa Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Saudi Arabia Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Turkey Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Argentina Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 51. UAE Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Egypt Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Chile Tenofovir Disoproxil Fumarate Tablets Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Global Tenofovir Disoproxil Fumarate Tablets Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Tenofovir Disoproxil Fumarate Tablets Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Tenofovir Disoproxil Fumarate Tablets Revenue (2021-2032) & (US$ Million) Figure 57. North America Tenofovir Disoproxil Fumarate Tablets Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Tenofovir Disoproxil Fumarate Tablets Revenue (2021-2032) & (US$ Million) Figure 59. Europe Tenofovir Disoproxil Fumarate Tablets Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Tenofovir Disoproxil Fumarate Tablets Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Tenofovir Disoproxil Fumarate Tablets Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Tenofovir Disoproxil Fumarate Tablets Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Tenofovir Disoproxil Fumarate Tablets Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Tenofovir Disoproxil Fumarate Tablets Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Tenofovir Disoproxil Fumarate Tablets Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Original Drug
  • Generic Drug
Applications
  • HIV-1 Infection
  • Chronic Hepatitis B
Companies covered
  • Aurobindo Pharma
  • Gilead Sciences
  • GSK
  • Hetero Drugs
  • Strides Pharma
  • Teva Pharmaceuticals
  • Chengdu Beite Pharmaceutical
  • Haisco Pharmaceutical
  • Shijiazhuang Lonzeal Pharmaceuticals
  • Luoxin Pharmaceuticals
  • Qilu Pharmaceutical
  • Shanghai Haini Pharmaceutical
  • Beijing SL Pharmaceutical
  • Sichuan Kelun Pharmaceutical
  • Chongqing Yaoyou Pharmaceutical
  • Zhejiang Sukean Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Tenofovir Disoproxil Fumarate Tablets Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Tenofovir Disoproxil Fumarate Tablets Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Tenofovir Disoproxil Fumarate Tablets Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Tenofovir Disoproxil Fumarate Tablets Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Tenofovir Disoproxil Fumarate Tablets Market Dynamics
  1. 2.1 Tenofovir Disoproxil Fumarate Tablets Industry Trends
  2. 2.2 Tenofovir Disoproxil Fumarate Tablets Industry Drivers
  3. 2.3 Tenofovir Disoproxil Fumarate Tablets Industry Opportunities and Challenges
  4. 2.4 Tenofovir Disoproxil Fumarate Tablets Industry Restraints
3 Tenofovir Disoproxil Fumarate Tablets Market by Manufacturers
  1. 3.1 Global Tenofovir Disoproxil Fumarate Tablets Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Tenofovir Disoproxil Fumarate Tablets Sales by Manufacturers (2021-2026)
  3. 3.3 Global Tenofovir Disoproxil Fumarate Tablets Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Tenofovir Disoproxil Fumarate Tablets Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Tenofovir Disoproxil Fumarate Tablets Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Tenofovir Disoproxil Fumarate Tablets Manufacturers, Product Type & Application
  7. 3.7 Global Tenofovir Disoproxil Fumarate Tablets Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Tenofovir Disoproxil Fumarate Tablets Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Tenofovir Disoproxil Fumarate Tablets Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Tenofovir Disoproxil Fumarate Tablets Tier 1, Tier 2, and Tier 3
4 Tenofovir Disoproxil Fumarate Tablets Market by Type
  1. 4.1 Tenofovir Disoproxil Fumarate Tablets Type Introduction
  2. 4.1.1 Original Drug
  3. 4.1.2 Generic Drug
  4. 4.2 Global Tenofovir Disoproxil Fumarate Tablets Sales by Type
  5. 4.2.1 Global Tenofovir Disoproxil Fumarate Tablets Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Tenofovir Disoproxil Fumarate Tablets Sales by Type (2021-2032)
  7. 4.2.3 Global Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Type (2021-2032)
  8. 4.3 Global Tenofovir Disoproxil Fumarate Tablets Revenue by Type
  9. 4.3.1 Global Tenofovir Disoproxil Fumarate Tablets Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Tenofovir Disoproxil Fumarate Tablets Revenue by Type (2021-2032)
  11. 4.3.3 Global Tenofovir Disoproxil Fumarate Tablets Revenue Market Share by Type (2021-2032)
5 Tenofovir Disoproxil Fumarate Tablets Market by Application
  1. 5.1 Tenofovir Disoproxil Fumarate Tablets Application Introduction
  2. 5.1.1 HIV-1 Infection
  3. 5.1.2 Chronic Hepatitis B
  4. 5.2 Global Tenofovir Disoproxil Fumarate Tablets Sales by Application
  5. 5.2.1 Global Tenofovir Disoproxil Fumarate Tablets Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Tenofovir Disoproxil Fumarate Tablets Sales by Application (2021-2032)
  7. 5.2.3 Global Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Application (2021-2032)
  8. 5.3 Global Tenofovir Disoproxil Fumarate Tablets Revenue by Application
  9. 5.3.1 Global Tenofovir Disoproxil Fumarate Tablets Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Tenofovir Disoproxil Fumarate Tablets Revenue by Application (2021-2032)
  11. 5.3.3 Global Tenofovir Disoproxil Fumarate Tablets Revenue Market Share by Application (2021-2032)
6 Global Tenofovir Disoproxil Fumarate Tablets Sales by Region
  1. 6.1 Global Tenofovir Disoproxil Fumarate Tablets Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tenofovir Disoproxil Fumarate Tablets Sales by Region (2021-2032)
  3. 6.2.1 Global Tenofovir Disoproxil Fumarate Tablets Sales by Region (2021-2026)
  4. 6.2.2 Global Tenofovir Disoproxil Fumarate Tablets Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Tenofovir Disoproxil Fumarate Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Tenofovir Disoproxil Fumarate Tablets Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Tenofovir Disoproxil Fumarate Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Tenofovir Disoproxil Fumarate Tablets Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Tenofovir Disoproxil Fumarate Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Tenofovir Disoproxil Fumarate Tablets Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Tenofovir Disoproxil Fumarate Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Tenofovir Disoproxil Fumarate Tablets Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Tenofovir Disoproxil Fumarate Tablets Revenue by Region
  1. 7.1 Global Tenofovir Disoproxil Fumarate Tablets Revenue by Region
  2. 7.1.1 Global Tenofovir Disoproxil Fumarate Tablets Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Tenofovir Disoproxil Fumarate Tablets Revenue by Region (2021-2026)
  4. 7.1.3 Global Tenofovir Disoproxil Fumarate Tablets Revenue by Region (2027-2032)
  5. 7.1.4 Global Tenofovir Disoproxil Fumarate Tablets Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Tenofovir Disoproxil Fumarate Tablets Revenue (2021-2032)
  8. 7.2.2 North America Tenofovir Disoproxil Fumarate Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Tenofovir Disoproxil Fumarate Tablets Revenue (2021-2032)
  11. 7.3.2 Europe Tenofovir Disoproxil Fumarate Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Tenofovir Disoproxil Fumarate Tablets Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Tenofovir Disoproxil Fumarate Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Tenofovir Disoproxil Fumarate Tablets Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Tenofovir Disoproxil Fumarate Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Aurobindo Pharma
  2. 8.1.1 Aurobindo Pharma Company Information
  3. 8.1.2 Aurobindo Pharma Business Overview
  4. 8.1.3 Aurobindo Pharma Tenofovir Disoproxil Fumarate Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Aurobindo Pharma Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  6. 8.1.5 Aurobindo Pharma Recent Developments
  7. 8.2 Gilead Sciences
  8. 8.2.1 Gilead Sciences Company Information
  9. 8.2.2 Gilead Sciences Business Overview
  10. 8.2.3 Gilead Sciences Tenofovir Disoproxil Fumarate Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Gilead Sciences Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  12. 8.2.5 Gilead Sciences Recent Developments
  13. 8.3 GSK
  14. 8.3.1 GSK Company Information
  15. 8.3.2 GSK Business Overview
  16. 8.3.3 GSK Tenofovir Disoproxil Fumarate Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GSK Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  18. 8.3.5 GSK Recent Developments
  19. 8.4 Hetero Drugs
  20. 8.4.1 Hetero Drugs Company Information
  21. 8.4.2 Hetero Drugs Business Overview
  22. 8.4.3 Hetero Drugs Tenofovir Disoproxil Fumarate Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Hetero Drugs Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  24. 8.4.5 Hetero Drugs Recent Developments
  25. 8.5 Strides Pharma
  26. 8.5.1 Strides Pharma Company Information
  27. 8.5.2 Strides Pharma Business Overview
  28. 8.5.3 Strides Pharma Tenofovir Disoproxil Fumarate Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Strides Pharma Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  30. 8.5.5 Strides Pharma Recent Developments
  31. 8.6 Teva Pharmaceuticals
  32. 8.6.1 Teva Pharmaceuticals Company Information
  33. 8.6.2 Teva Pharmaceuticals Business Overview
  34. 8.6.3 Teva Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Teva Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  36. 8.6.5 Teva Pharmaceuticals Recent Developments
  37. 8.7 Chengdu Beite Pharmaceutical
  38. 8.7.1 Chengdu Beite Pharmaceutical Company Information
  39. 8.7.2 Chengdu Beite Pharmaceutical Business Overview
  40. 8.7.3 Chengdu Beite Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Chengdu Beite Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  42. 8.7.5 Chengdu Beite Pharmaceutical Recent Developments
  43. 8.8 Haisco Pharmaceutical
  44. 8.8.1 Haisco Pharmaceutical Company Information
  45. 8.8.2 Haisco Pharmaceutical Business Overview
  46. 8.8.3 Haisco Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Haisco Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  48. 8.8.5 Haisco Pharmaceutical Recent Developments
  49. 8.9 Shijiazhuang Lonzeal Pharmaceuticals
  50. 8.9.1 Shijiazhuang Lonzeal Pharmaceuticals Company Information
  51. 8.9.2 Shijiazhuang Lonzeal Pharmaceuticals Business Overview
  52. 8.9.3 Shijiazhuang Lonzeal Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Shijiazhuang Lonzeal Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  54. 8.9.5 Shijiazhuang Lonzeal Pharmaceuticals Recent Developments
  55. 8.10 Luoxin Pharmaceuticals
  56. 8.10.1 Luoxin Pharmaceuticals Company Information
  57. 8.10.2 Luoxin Pharmaceuticals Business Overview
  58. 8.10.3 Luoxin Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Luoxin Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  60. 8.10.5 Luoxin Pharmaceuticals Recent Developments
  61. 8.11 Qilu Pharmaceutical
  62. 8.11.1 Qilu Pharmaceutical Company Information
  63. 8.11.2 Qilu Pharmaceutical Business Overview
  64. 8.11.3 Qilu Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Qilu Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  66. 8.11.5 Qilu Pharmaceutical Recent Developments
  67. 8.12 Shanghai Haini Pharmaceutical
  68. 8.12.1 Shanghai Haini Pharmaceutical Company Information
  69. 8.12.2 Shanghai Haini Pharmaceutical Business Overview
  70. 8.12.3 Shanghai Haini Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Shanghai Haini Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  72. 8.12.5 Shanghai Haini Pharmaceutical Recent Developments
  73. 8.13 Beijing SL Pharmaceutical
  74. 8.13.1 Beijing SL Pharmaceutical Company Information
  75. 8.13.2 Beijing SL Pharmaceutical Business Overview
  76. 8.13.3 Beijing SL Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Beijing SL Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  78. 8.13.5 Beijing SL Pharmaceutical Recent Developments
  79. 8.14 Sichuan Kelun Pharmaceutical
  80. 8.14.1 Sichuan Kelun Pharmaceutical Company Information
  81. 8.14.2 Sichuan Kelun Pharmaceutical Business Overview
  82. 8.14.3 Sichuan Kelun Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Sichuan Kelun Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  84. 8.14.5 Sichuan Kelun Pharmaceutical Recent Developments
  85. 8.15 Chongqing Yaoyou Pharmaceutical
  86. 8.15.1 Chongqing Yaoyou Pharmaceutical Company Information
  87. 8.15.2 Chongqing Yaoyou Pharmaceutical Business Overview
  88. 8.15.3 Chongqing Yaoyou Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Chongqing Yaoyou Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  90. 8.15.5 Chongqing Yaoyou Pharmaceutical Recent Developments
  91. 8.16 Zhejiang Sukean Pharmaceutical
  92. 8.16.1 Zhejiang Sukean Pharmaceutical Company Information
  93. 8.16.2 Zhejiang Sukean Pharmaceutical Business Overview
  94. 8.16.3 Zhejiang Sukean Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Zhejiang Sukean Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  96. 8.16.5 Zhejiang Sukean Pharmaceutical Recent Developments
  97. 8.17 Chia Tai Tianqing Pharmaceutical
  98. 8.17.1 Chia Tai Tianqing Pharmaceutical Company Information
  99. 8.17.2 Chia Tai Tianqing Pharmaceutical Business Overview
  100. 8.17.3 Chia Tai Tianqing Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Chia Tai Tianqing Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  102. 8.17.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tenofovir Disoproxil Fumarate Tablets Value Chain Analysis
  2. 9.1.1 Tenofovir Disoproxil Fumarate Tablets Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tenofovir Disoproxil Fumarate Tablets Production Mode & Process
  6. 9.2 Tenofovir Disoproxil Fumarate Tablets Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tenofovir Disoproxil Fumarate Tablets Distributors
  9. 9.2.3 Tenofovir Disoproxil Fumarate Tablets Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst